Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters, Sangeeta Sawhney, Paul Strumph. Diabetes Care 2018
Times Cited: 76
Times Cited: 76
David R Powell, Melinda Smith, Jennifer Greer, Angela Harris, Sharon Zhao, Christopher DaCosta, Faika Mseeh, Melanie K Shadoan, Arthur Sands, Brian Zambrowicz, Zhi-Ming Ding. J Pharmacol Exp Ther 2013
Times Cited: 109
Times Cited: 109
List of shared articles
Times cited
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Elena Paschetta. BMJ 2019
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Elena Paschetta. BMJ 2019
The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
Daniël H van Raalte, Petter Bjornstad, Frederik Persson, David R Powell, Rita de Cassia Castro, Ping Stella Wang, Minzhi Liu, Hiddo J L Heerspink, David Cherney. Diabetes Care 2019
Daniël H van Raalte, Petter Bjornstad, Frederik Persson, David R Powell, Rita de Cassia Castro, Ping Stella Wang, Minzhi Liu, Hiddo J L Heerspink, David Cherney. Diabetes Care 2019
Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
Kajal Patel, Antonia Carbone. Ann Pharmacother 2019
Kajal Patel, Antonia Carbone. Ann Pharmacother 2019
Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes.
Marc S Rendell. Expert Rev Endocrinol Metab 2018
Marc S Rendell. Expert Rev Endocrinol Metab 2018
What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Jessica A Dominguez Rieg, Timo Rieg. Diabetes Obes Metab 2019
Jessica A Dominguez Rieg, Timo Rieg. Diabetes Obes Metab 2019
The journey from gene knockout to clinical medicine: telotristat and sotagliflozin.
Marc S Rendell. Drug Des Devel Ther 2019
Marc S Rendell. Drug Des Devel Ther 2019
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
David R Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc Hellerstein, Phillip Banks, Paul Strumph, Pablo Lapuerta. J Clin Endocrinol Metab 2020
David R Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc Hellerstein, Phillip Banks, Paul Strumph, Pablo Lapuerta. J Clin Endocrinol Metab 2020